Management of Severe Gastritis

Immediate Treatment Approach

The American College of Gastroenterology recommends high-potency proton pump inhibitors (PPIs) such as esomeprazole 20-40 mg or rabeprazole 20 mg twice daily as the first-line treatment for severe gastritis, taken 30 minutes before meals for optimal effectiveness 1, 2
High-potency PPIs, such as esomeprazole 20-40 mg twice daily or rabeprazole 20 mg twice daily, are preferred for severe gastritis due to their superior efficacy compared to standard-potency options 1, 2
Lansoprazole 30 mg twice daily is an alternative high-potency option for patients who cannot tolerate esomeprazole or rabeprazole 1
PPIs must be taken 30 minutes before meals to maximize effectiveness, and treatment duration should be at least 8 weeks for healing of erosive changes 1, 2

All patients with severe gastritis must be tested for H. pylori infection using non-invasive methods, such as urea breath test or monoclonal stool antigen test, as recommended by the American Gastroenterological Association 2, 3
The use of serological testing for H. pylori is not recommended as it remains positive after eradication and cannot confirm treatment success 3
If H. pylori is positive, eradication therapy is mandatory regardless of symptom severity, according to the National Institute of Diabetes and Digestive and Kidney Diseases 1, 2

Bismuth quadruple therapy for 14 days is the first-line treatment for H. pylori eradication due to increasing antibiotic resistance, as recommended by the Infectious Diseases Society of America 1, 2, 3
The regimen includes a high-potency PPI, bismuth subsalicylate, metronidazole, and tetracycline, and concomitant 4-drug therapy is an alternative when bismuth is unavailable 1, 2, 3
Prioritize "Access group" antibiotics, such as amoxicillin, tetracycline, and metronidazole, over "Watch group" antibiotics, such as clarithromycin and levofloxacin, to minimize resistance 2, 3

For patients at high risk of gastritis complications, such as those taking NSAIDs or anticoagulants, add PPI or H2-blocker prophylaxis during corticosteroid therapy, as recommended by the National Comprehensive Cancer Network 4
Long-term PPI treatment in H. pylori-positive patients accelerates progression to corpus-predominant atrophic gastritis, and eradication of H. pylori is necessary before initiating chronic PPI therapy 1, 3

Inadequate PPI dosing or incorrect timing reduces effectiveness, and premature discontinuation of treatment before 8 weeks prevents adequate mucosal healing 1, 2
Failure to test for and eradicate H. pylori when present leads to persistent inflammation and cancer risk, and using antibiotic courses shorter than 14 days results in treatment failure 1, 2
Relying on symptom resolution without confirming H. pylori eradication allows persistent infection, and prescribing long-term PPIs without first eradicating H. pylori accelerates progression to atrophic gastritis 1, 3

The American Gastroenterological Association recommends testing for successful H. pylori eradication 4-6 weeks after completing antibiotic therapy using non-serological methods, such as urea breath test or monoclonal stool antigen test, and ensuring the patient has been off PPI therapy for at least 2 weeks before testing to avoid false-negative results 5, 6
The European Society for Gastrointestinal Endoscopy suggests that H. pylori eradication is recommended for gastric cancer prevention, especially before development of preneoplastic conditions like atrophic gastritis, and delaying treatment allows continued mucosal damage and progression toward atrophy 6

The American College of Gastroenterology recommends that all patients with atrophic gastritis or erosive gastritis should be assessed for H. pylori and treated if positive, and patients with corpus-predominant gastritis should be evaluated for iron and vitamin B-12 deficiencies 5
The British Society of Gastroenterology suggests that first-degree relatives of patients with gastric cancer should receive H. pylori eradication as they are at 2-3 times increased risk, and if a patient is taking NSAIDs or aspirin, H. pylori eradication is mandatory before continuing these medications, as H. pylori increases risk of NSAID-associated ulcers 6, 7